Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Linker (Cleavable, Non-cleavable), By Condition (Myeloma, Lymphoma, Breast Cancer), By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Antibody Drug Conjugates Contract Manufacturing market size accounted for USD 9.85 billion in 2022 and is estimated to achieve a market size of USD 26.18 billion by 2030 growing at a CAGR of 12.18% from 2022 to 2030.

Key Takeaways:

  • By condition, the lymphoma segment is expected to grow at the fastest CAGR over the forecast period
  • A significant number of ADCs under development for lymphoma and collaborations for ADC-related research for lymphoma are supporting the growth of the segment over the forecast period
  • Based on the linker, the cleavable linker segment accounted for the maximum share of the overall revenue in 2022
  • Extensive use of cleavable linker technology in ADC and a greater number of cleavable linker-based products in the pipeline are the factors responsible for the segment growth
  • Asia Pacific dominated the global industry in 2022 and accounted for the maximum revenue share
  • This is due to the robust improvements in R&D activities in emerging markets and low-cost manufacturing in the region as compared to that of developed countries

The industry is anticipated to witness significant growth over the forecast period on account of the increasing prevalence of cancer, rising demand for biologic therapy, and the challenges associated with antibody drug conjugate (ADC) manufacturing, which contribute to the demand for contract manufacturing. During Q1 and Q2 of 2020, due to the global COVID-19 pandemic, the supply chain was disrupted due to stay-at-home orders by governments across the globe to control the spread of the virus.

The factors driving the industry growth include the complex nature of antibody drug conjugates (ADCs) contributing to the demand for contract manufacturing, the increasing number of research on antibody therapies, and the rise in cancer incidence. During the pandemic, the clinical trials for cancer were stopped for a short period. However, owing to the severity of the disease, the trials were started again. As per the IQVIA Oncology Trends Report 2022, the number of clinical trials for cancer is growing.

The IQVIA report states that there was a 56% increase in oncology clinical trials between 2016 and 2021. This number of clinical studies is expected to rise even further owing to the growing prevalence of cancer worldwide. This is expected to support the ADC development and manufacturing activities, thus supporting industry growth post-pandemic. Antibody drug conjugates have high efficiency in treating cancer as it only targets the cancerous cells and does not affect the healthy cells of the body. As a result, several biopharmaceutical companies have received significant funding for ADC-related research.

For instance, in October 2022, Mablink Bioscience, raise USD 31 million from Series A funding to build its antibody drug conjugate pipeline. Thus, heavy investments in the R&D of ADCs are expected to improve their availability in the coming years and thus support the demand for ADC contract manufacturing. In September 2021, the U.S. FDA provided accelerated approval for ADC tisotumab vedotin-tftv for treating adult patients with recurrent or metastatic cervical cancer with disease progression or after chemotherapy. Such approvals, in the coming years, are expected to boost the demand for contract manufacturing services for ADC.

Report Scope of the Antibody Drug Conjugates Contract Manufacturing Market

Report Coverage


Market Size

USD 26.18 Billion by 2030

Growth Rate

CAGR of 12.18% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year


Forecast Period

2022 to 2030

Segments Covered

Condition, linker and Region,

Companies Mentioned

Sterling; Recipharm AB; Lonza; Catalent, Inc.; Sartorius AG; Wuxi Biologics; Samsung BioLogics; Piramal Group (Piramal Pharma Solutions); Abbvie, Inc. (Abbvie Contract Manufacturing); Merck KGaA


Condition Insights

The myeloma segment dominated the industry and accounted for the largest revenue share of more than 49.55% in 2022. Based on the condition, the industry is segmented into myeloma, lymphoma, breast cancer, and others (urothelial cancer and cervical cancer). ADCs for myeloma is a novel type of treatment that delivers a powerful cytotoxic chemical only to the myeloma cell. This mode of action reduces bystander cell damage and opens up a therapeutic window. ADCs have a high potential for use in the treatment of myeloma as they are “off-the-shelf” therapies. It can be utilized in almost all myeloma treatment clinics and for a diverse spectrum of patients. These factors are supporting ADCs demand for myeloma treatment and thus contributing to the segment growth.

The lymphoma segment is expected to register the fastest CAGR over the forecast period. Lymphoma affects a significant number of people worldwide. According to Cancer Tomorrow, in 2020, 83,100 cases of Hodgkin lymphoma were reported globally, while over 544,000 cases of non-Hodgkin lymphoma were reported. Currently, there are three approved ADC products for lymphoma: Adcetris, Polivy, and Zynlonta. Among the commercially available ADCs, the majority are used for the treatment of lymphoma and breast cancer. The segment is supported by a large number of commercially available ADCs used for treating lymphoma. As of 2021, over 10 ADC for Lymphoma is under the preclinical and clinical stage of development. This is likely to improve the demand for its contract manufacturing during the forecasted period.

Linker Insights

Based on linkers, the industry is segmented into cleavable and non-cleavable linkers. The cleavable linker segment dominated the industry in 2022 and accounted for the highest share of more than 56.10% of the overall revenue. The segment is likely to remain dominant over the coming years. A major factor that influences the growth of this segment is the advantages that cleavable linkers offer in certain circumstances to deliver the medication to the target cell. The characteristics of the linker between the antibody and the payload are seen as crucial to an ADC’s success. The capacity of cleavable linkers to efficiently distinguish between circulatory and target-cell circumstances accounts for their effectiveness.

The non-cleavable linker segment is expected to register the fastest CAGR over the forecast period. ADCs produced using a non-cleavable linker are reliant on the ADC’s lysosomal degradation, which releases the cytotoxic molecules after the ADC molecule has been internalized in the target cell. This prevents the non-specific release of the drug, thus reducing the overall cytotoxicity of the ADC to surrounding healthy cells. Furthermore, one of the major advantages of non-cleavable linkers is that they have higher plasma stability than cleavable linkers, thus increasing the therapeutic window, they also have a longer half-life in circulation. The above-listed factors are supporting the segment growth.

Regional Insights

In terms of region, Asia Pacific dominated the global industry in 2022 and accounted for the maximum share of more than 40.25%  of the overall revenue. It is expected to remain dominant growing at the fastest CAGR during the forecast period. This region has a high burden of cancer as compared to other regions. According to Cancer Tomorrow,9.4 million cases of cancer were reported in 2020 in Asia, and this number is expected to rise to 14.2 million by 2040. Thus, a rise in the cancer cases is expected to boost the demand for targeted therapies like ADC for treatment, thereby supporting its demand for manufacturing. In addition, the cost of contract manufacturing in Asia Pacific countries is relatively low compared to that in developed economies.

Thus, it further supports regional market growth. North America also accounted for a considerable revenue share in 2022. This growth can be attributed to the increasing number of biopharmaceutical companies within the U.S. and Canada. The presence of a large number of major players in this region is expected to contribute significantly to the region’s growth. Moreover, the regulatory authority in the region is actively providing regulatory approval for ADCs. For instance, the USFDA has approved 12 ADCs as of 2021. This improves its commercial availability and, thus, supports its adoption in the region. The above-mentioned factors are boosting regional market growth.

Some of the prominent players in the Antibody Drug Conjugates Contract Manufacturing Market include:

  • Sterling
  • Recipharm AB
  • Lonza
  • Catalent, Inc.
  • Sartorius AG
  • Wuxi Biologics
  • Samsung BioLogics
  • Piramal Group (Piramal Pharma Solutions)
  • Abbvie, Inc. (Abbvie Contract Manufacturing)
  • Merck KGaA

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Antibody Drug Conjugates Contract Manufacturing market

  • Condition
    • Myeloma
    • Lymphoma
    • Breast Cancer
    • Others (Urothelial Cancer)
  • Linker
    • Cleavable Linker
    • Non-cleavable Linker

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Antibody Drug Conjugates Contract Manufacturing industry analysis from 2022 to 2030 to identify the prevailing Antibody Drug Conjugates Contract Manufacturing industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Antibody Drug Conjugates Contract Manufacturing industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Antibody Drug Conjugates Contract Manufacturing industry trends, key players, market segments, application areas, and market growth strategies.

Report Detail

  • Report Code:7551
  • No. of Pages:150+
  • Format:PDF/PPT/Excel

Proceed To Buy

USD 3500
USD 7000